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Background-—During a myocardial infarction, no single best approach of systemic anticoagulation is recommended, likely due to a
lack of comparative effectiveness studies and trade-offs between treatments.
Methods and Results-—We investigated the patterns of use and site-level variability in anticoagulant strategies (unfractionated
heparin [UFH] only, low-molecular-weight heparin [LMWH] only, UFH+LMWH, any bivalirudin) of 63 796 patients with a principal
diagnosis of myocardial infarction treated with an early invasive strategy with percutaneous coronary intervention at 257 hospitals.
About half (47%) of patients received UFH only, 6% UFH+LMWH, 7% LMWH only, and 40% bivalirudin. Compared with UFH, the
median odds ratio was 2.90 for LMWH+UFH, 4.70 for LMWH only, and 3.09 for bivalirudin, indicating that 2 “identical” patients
would have a 3- to 4-fold greater likelihood of being treated with anticoagulants other than UFH at one hospital compared with
another. We then categorized hospitals as low- or high-users of LMWH and bivalirudin. Using hierarchical, multivariate regression
models, we found that low bivalirudin-using hospitals had higher unadjusted bleeding rates, but the risk-adjusted and
anticoagulant-adjusted bleeding rates did not differ across the hospital anticoagulation phenotypes. Risk-standardized mortality
and risk-standardized length of stay also did not differ across hospital phenotypes.
Conclusions-—We found substantial site-level variability in the choice of anticoagulants for invasively managed acute myocardial
infarction patients, even after accounting for patient factors. No single hospital-use pattern was found to be clinically superior.
More studies are needed to determine which patients would derive the greatest benefit from various anticoagulants and to support
consistent treatment of patients with the optimal anticoagulant strategy. ( J Am Heart Assoc. 2015;4:e002009 doi: 10.1161/
JAHA.115.002009)
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S ystemic anticoagulation is a core treatment for acutemyocardial infarction (MI) that is supported by both
European1,2 and American3,4 guidelines. Despite this strong
recommendation for anticoagulation and many studies in
this area, no single best approach has been endorsed.5–8
This is, in part, due to a limited number of comparative
effectiveness studies, as new anticoagulant therapies are
typically compared with unfractionated heparin (UFH). In
addition, there are trade-offs between anticoagulants in
terms of ischemic outcomes, bleeding, and costs. For
example, bivalirudin reduces the risk of bleeding compared
with UFH among invasively managed MI patients6,8 but at
increased costs,9 although a recent clinical trial failed to find
an advantage for bivalirudin for patients with ST-elevation
MI undergoing primary percutaneous coronary interven-
tion (PCI) using a primarily radial access.10 As such, the
optimal strategy for anticoagulation across the population of
patients with different risk profiles has not been firmly
established.
Despite uncertainty concerning therapeutic options, prac-
tice patterns within hospitals sometimes coalesce around
particular treatments. Accordingly, there may be consistency
in local practice patterns that differs substantially from that of
other hospitals based on physician preferences rather than
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ORIGINAL RESEARCH
patients’ characteristics or risk profiles.11–13 Understanding
the patterns of care across institutions and their association
with outcomes could provide the foundation for comparative
effectiveness studies and targets for practice improvement
where substantial deviation from existing evidence is
observed. As such, we sought to better characterize practice
patterns of use of anticoagulants (or hospital phenotypes)
among patients with an MI who were treated with PCI across
a broad sample of US hospitals; identify patient and practice
factors associated with these patterns; and examine whether
these patterns are associated with clinical outcomes. We used
a database that has complete hospital-level resource utiliza-




We derived the study sample from a database maintained by
Premier, Inc, Charlotte, NC.14 Premier is the nation’s largest
hospital performance-improvement alliance. The Premier
database contains administrative, operational, and limited
clinical information that includes patient daily service records
for 26% of hospital discharges in the United States. It includes
all geographical areas of the United States and a broad range
of hospital types in terms of bed size, teaching status, and
urban or rural population served. In addition to the informa-
tion available in the standard hospital discharge files, the
database contains a date-stamped log of all billed items and
related costs during hospitalizations at the patient level,
including medications and laboratory, diagnostic, and thera-
peutic services. The database also contains information on
patient age, sex, race, admission type, discharge status, and
primary payer.
All data were de-identified in accordance with the Health
Insurance Portability and Accountability Act. As a retrospec-
tive study using de-identified patient and provider data, the
Yale University Human Investigation Committee exempted the
protocol from review by the Office of Human Research
Protections.
Study Cohort
We included hospitalizations from January 1, 2009 to
December 31, 2011 for patients with a principal discharge
diagnosis of MI (International Classification of Diseases, Ninth
Revision, Clinical Modification [ICD-9-CM] code 410.xx,
excluding those with 410.x2). In accord with recent work by
Yeh et al, a code of 410.7x was classified as a non-ST-
elevation MI; all other codes were considered ST-elevation
MI.15 To ensure a study group of patients with similar
treatment goals, we further restricted the analytic population
to those who were treated invasively within the first 2 days of
hospitalization (ie, had coronary angiogram performed
between hospital day 0 to 2), received PCI, and were treated
with UFH (subcutaneous UFH was excluded), low-molecular-
weight heparin (LMWH), or bivalirudin. Patients were excluded
if they underwent coronary artery bypass graft surgery during
the hospitalization, were <18 years of age, were assigned a
pediatrician as the attending physician of record, or had a
length of stay <1 day. As we were examining hospital-level
variability in the use of anticoagulants and its associations
with outcomes, we excluded patients who were transferred
from another hospital (ie, the anticoagulation management
was not solely under the control of the enrolling hospital) or
admitted to a hospital with <25 cases during the study period
(due to the inability to accurately categorize their anticoag-
ulant practice patterns).
Patient comorbidities were defined using the Healthcare
Cost and Utilization Project software, as described by
Elixhauser et al.16 As per prior work,17 in-hospital bleeding
events were identified using secondary ICD-9-CM diagnosis
codes (Table 1). PCIs performed during the MI hospitalization
were identified using standard charge codes, and coronary
artery bypass grafts were identified using ICD-9-CM proce-
dure code 31.6x.
Anticoagulants and Hospital Phenotypes
Anticoagulant use was reviewed from admission day (day 0) to
day 2. Anticoagulant use that did not meet MI treatment
levels was excluded to avoid misclassification of doses given
for other indications (eg, prophylaxis for deep vein thrombo-
sis, catheter flushes). The minimum anticoagulant doses
considered as treatment for the MI were 1000 U IV UFH
(cumulative dose), 60 mg enoxaparin, 7200 IU of dalteparin,
or 10 000 U of tinzaparin.18 As patients could receive >1
anticoagulant during their hospitalization, patients were
categorized into the most common groups of cardiac
anticoagulation use: any bivalirudin use, UFH only, LMWH
only, and UFH+LMWH. Although patients who receive biva-
lirudin in the catheterization laboratory could receive another
anticoagulant before the procedure, their clinical outcomes, in
terms of bleeding and ischemic outcomes, have been
previously determined to be similar to those of patients who
received bivalirudin only.19–21
The frequency for each anticoagulant strategy was first
calculated for each hospital. Hospitals were then categorized
as being high versus low users of bivalirudin (based on above
versus below the median of 37.4% (interquartile range 18.4%
to 66.5%) and high versus low users of LMWH (based on above
versus below the median of 9.8% (interquartile range 4.8% to
19.7%). We used these categories to construct 4 anticoagulant
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phenotypes: low bivalirudin/low LMWH (ie, predominate users
of UFH), low bivalirudin/high LMWH, high bivalirudin/low
LMWH, and high bivalirudin/high LMWH. We also performed a
sensitivity analysis that reclassified hospitals using a threshold
of above the third quartile of bivalirudin and LMWH use to
define high users of these anticoagulants (ie, a high bivalirudin-
using hospital was defined as use >66.5%; a high LMWH-using
hospital was defined as use >19.7%).
Statistical Analysis
The variability in the use of different anticoagulant treatment
strategies across sites was assessed using a hierarchical
multinomial logistic regression model with anticoagulant
choice as the dependent variable and adjusting for patient
age, sex, ST-elevations at admission, select comorbidities
(Table 2), and use of concomitant glycoprotein IIb/IIIa
inhibitors. All variables were first entered in a nonhierarchical
multivariate model, which was then reduced using backward
elimination. Covariates identified in this model as signifi-
cantly associated with anticoagulant treatment strategy were
then included in the final hierarchical model. Variability
between hospitals was quantified using the median odds
ratio (with UFH only as reference), which estimates the
average difference in odds ratios of 2 hypothetical patients
with identical clinical characteristics being treated with
different anticoagulant strategies if they presented to 2
random hospitals in the dataset. Also, to estimate the
contribution to variation by local practice patterns (hospital
effect), we calculated the intraclass correlation coefficient for
each anticoagulant strategy with UFH treatment (only) as
reference.22
After phenotyping hospitals according to their unadjusted
anticoagulant practice patterns (as described above), we used
multiple logistic regression with multinomial outcomes to
assess the association between hospital anticoagulant use
phenotype and hospital characteristics. To do this, we
calculated the odds ratio of a patient being treated at each
anticoagulant phenotype hospital (reference: low bivalirudin/
low LMWH) in relation to hospital characteristics (hospital
population served [rural versus urban], teaching status,
number of beds, and geographic region) after adjusting for
other patient characteristics.
For clinical outcomes, we first used logistic regression to
assess the patient-level association between bleeding events
and different anticoagulant treatment strategies, adjusting for
patient characteristics and percutaneous and surgical revas-
cularization. Then, we assessed each hospital’s risk-standard-
ized bleeding rates (RSBRs), risk-standardized in-hospital
mortality rates (RSMRs), and risk-standardized lengths of stay
(RSLOS). Similar to above, all variables were entered into a
nonhierarchical multivariable model and the model was
reduced using backward elimination. For each hospital, we
calculated 2 RSBRs using hierarchical logistic regressions: first
adjusting for patient characteristics, PCI, and coronary artery
bypass grafts, then additionally adjusting for anticoagulant
treatment strategies. All significant predictors of bleeding
identified in the model above were included for risk standard-
ization. RSMR was similarly calculated using hierarchical
logistic regression. A hierarchical generalized linear model
with a logarithmic link and Poisson distribution was used to
derive RSLOS for each hospital, which was the product of
national average LOS and the ratio of average predicted LOS to
average expected LOS. The RSBRs, RSMRs, and RSLOS were
then compared across the 4 hospital anticoagulant pheno-
types using the Kruskal–Wallis test. These methods are
consistent with those used by the Centers for Medicare &
Medicaid Services to calculate risk-standardized outcomes.23
All statistical analyses were performed using SAS 9.3 (SAS
Institute, Inc, Cary, NC) and a 2-sided P-value of <0.05 was
used to determine statistical significance. Analyses were
Table 1. ICD-9-CM Codes Used to Define a Bleeding Event
ICD-9-CM Code Description
285.1 Anemia, acute posthemorrhagic




531.0 Acute stomach ulcer with hemorrhage
532.0 Acute duodenal ulcer with hemorrhage
532.2 Acute duodenal ulcer with hemorrhage and perforation
533.0 Acute peptic ulcer with hemorrhage
533.2 Acute peptic ulcer with hemorrhage and perforation
533.4 Chronic peptic ulcer with hemorrhage
533.6 Chronic peptic ulcer with hemorrhage and perforation
569.3 Hemorrhage, rectal and anal
569.85 Angiodysplasia of intestine with hemorrhage
578.0 Hematemesis
578.1 Blood in stool
578.9 Hemorrhage, gastrointestinal NOS
599.7 Hematuria
626.8 Disorder, menstrual NEC
626.9 Disorder, menstrual NOS
627.1 Bleeding, postmenopausal
729.92 Nontraumatic hematoma soft tissue
786.3 Hemoptysis
998.1 Hemorrhage complicating a procedure
ICD-9-CM indicates International Classification of Diseases, Ninth Revision, Clinical
Modification; NEC, not elsewhere classifiable; NOS, not otherwise specified.
DOI: 10.1161/JAHA.115.002009 Journal of the American Heart Association 3



















During the study period, we identified 281 842 MI hospital-
izations within the Premier database (Figure 1). We excluded
148 396 patients whose MIs were managed medically or
surgically, 18 189 patients who were not treated with an early
invasive strategy, and 26 237 patients who did not receive an
anticoagulant during the first 2 days of hospitalization. After
excluding an additional 25 194 patients who were <18 years
of age, were treated by a pediatrician, were transferred from
another hospital, had a length of stay <1 day, or were
admitted by a hospital with <25 cases, our final analytic
cohort totaled 63 796 patients treated invasively for an MI at
257 hospitals. The median age of the population was
61 years, one third were female, and 57% presented with
ST-elevations. Of these patients, 47% were treated with UFH
only, 6% were treated with a combination of UFH and LMWH,
7% received LMWH only, and 40% were treated with any
Table 2. Demographic and Clinical Characteristics of Patients Treated With Different Anticoagulants
Total (n=63 796) UFH Only (n=30 230) UFH+LMWH (n=3574) LMWH Only (n=4406) Any Bivalirudin (n=25 586)
Age, median (IQR) 61 (53 to 71) 60 (52 to 70) 61 (53 to 72) 62 (53 to 72) 62 (53 to 72)
Female, % 31.0 29.9 31.5 33.4 31.8
Hypertension, % 67.2 65.5 68.9 70.8 68.3
Congestive heart failure, % 0.2 0.2 0.2 0.2 0.2
Peripheral vascular disease, % 8.6 8.3 10.1 9.9 8.5
Diabetes with complications, % 3.5 3.4 3.7 3.5 3.7
Renal failure, % 9.6 9.3 9.7 8.9 10
Chronic pulmonary disease, % 14.7 14.5 14.3 16.9 14.6
Liver disease, % 1.0 1.0 0.9 1.0 0.9
Weight loss, % 1.3 1.3 0.9 1.3 1.2
Deficiency anemia, % 10.3 10.7 10.6 9.5 10.0
Chronic blood loss anemia, % 0.6 0.7 0.5 0.6 0.5
Coagulopathy, % 3.3 3.7 2.7 2.9 3.0
Fluid and electrolyte disorders, % 13.3 13.8 14.0 12.7 12.8
Metastatic cancer, % 0.4 0.4 0.4 0.5 0.5
Solid tumor without metastasis, % 1.0 0.9 0.8 0.9 1.0
Paralysis, % 0.8 0.8 0.8 0.9 0.9
ST-elevation MI, % 57 67.3 36.6 32.1 52.1
Glycoprotein IIb/IIIa inhibitor, % 57.5 77.0 75.1 67.0 30.4
Dual antiplatelet pretreatment, % 28.0 25.2 27.0 21.2 32.7




Patients with AMI treated 
with early invasive strategy
N=115,227
Patients with AMI treated with early




Medically or surgically managed
N=148,376
No angiogram within first 2 days
N=18,189
No anticoagulant
within first 2 days
N=26,237
Patient age <18 years
Transfer to/from another hospital
Pediatrician is attending physician
Length of stay <1 day
Hospital case volume <25
N=25,194
Figure 1. Flowchart of patients. AMI indicates acute myocardial
infarction.
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bivalirudin. The demographic and clinical characteristics of
patients treated with different anticoagulant strategies are
shown in Table 2.
Hospital Variability and Phenotypes
The patterns of use of the different anticoagulants varied
substantially across the sample of hospitals (Figure 2). The
median (interquartile range) use of UFH among the hospitals
was 45.8% (19.0% to 65.0%), UFH+LMWH 4.2% (1.0% to
10.8%), LMWH only 4.2% (1.0% to 10.8%), and any bivalirudin
37.4% (18.4% to 66.5%). In the hierarchical, multivariate
model adjusted for patient characteristics, there was
substantial site-level variability in the anticoagulant strategy.
For example, compared with a strategy of UFH, the median
odds ratio was 2.90 for LMWH+UFH, indicating that 2
“identical” patients would have an almost 3-fold greater
likelihood of being treated with LMWH+UFH at 1 hospital as
compared with another. Similarly, the median odds ratio for
LMWH only and bivalirudin were 4.70 and 3.09, respectively.
Furthermore, the amount of variability in the use of antico-
agulants that could be attributed to hospital-level variation (as
opposed to patient-level differences), as measured with the
intraclass correlation coefficient with UFH only as the
reference group, was 28% for UFH+LMWH, 45% for LMWH
only, and 30% for bivalirudin.
We then categorized hospitals based on their observed
practice patterns: high bivalirudin/high LMWH (n=54), high
bivalirudin/low LMWH (n=75), low bivalirudin/high LMWH
(n=74), and low bivalirudin/low LMWH (n=54). The median
use of each of the 4 anticoagulant strategies among the
hospitals in the different anticoagulant use phenotypes is
shown in Figure 3. As expected, the anticoagulant treatment
strategies varied substantially among different anticoagulant
use phenotypes; for example, the median proportion of UFH
only ranged from 18% in high bivalirudin/high LMWH
hospitals to 77% in low bivalirudin/low LMWH hospitals. In
the multivariate model assessing institutional factors with a
hospital’s anticoagulant phenotype, rural hospitals were
more likely to be high users of bivalirudin (Table 3), while
teaching hospitals and hospitals with >400 beds were more
likely to be low bivalirudin/low LMWH (ie, UFH only)
hospitals. Finally, hospitals in the West census region were
more likely to be higher users of bivalirudin, particularly in
comparison with hospitals in the Northeast. Hospitals in the
South and Midwest census regions were higher users of
LMWH.
Outcomes
The demographic and clinical factors associated with

















































Figure 2. Unadjusted use of each anticoagulation strategy across the 262 hospitals. LMWH indicates
low-molecular-weight heparin; UFH, unfractionated heparin.
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and include factors such as older age, heart failure, lung
disease, weight loss, anemia, and coagulopathy. At the patient
level, bivalirudin (any) was associated with a lower risk of in-
hospital bleeding compared with UFH, while patients treated
with LMWH or a combination of UFH and LMWH had similar
bleeding risk compared with UFH only.
We then examined the outcomes according to the
hospital’s anticoagulant use phenotype. In unadjusted analy-
sis, there was a difference in the rate of bleeding events
across the 4 phenotypes, with the 2 high bivalirudin
phenotypes having the lowest reported rates of bleeding at
3.4%, the low bivalirudin/high LMWH 4.0%, and low bivaliru-
din/low LMWH 4.4% (Table 5; P=0.033). However, there was
no significant difference in RSBRs after adjusting for patient
characteristics or anticoagulant treatment. In addition, there
were no significant differences in RSMR or RSLOS across the
4 phenotypes (Table 5).
In the sensitivity analysis using the upper quartile of use to
define high-users of bivalirudin and LMWH, there were no
differences in unadjusted, risk-adjusted, or anticoagulant-
adjusted bleeding rates, and RSMRs across the 4 hospital
phenotypes (Table 6). RSLOS was slightly shorter at high
bivalirudin-using hospitals.
Discussion
In a study of 63 796 MI patients from 257 US hospitals, we
found substantial site-level variability with regard to choice of
anticoagulant strategy, even after accounting for patient
factors, with >25% of the variability in anticoagulant choice
attributable just to local practice patterns. This indicates that
the preferences of the treating hospital (presumably through
its physicians) play a substantial role in the anticoagulant
strategy selected for patients, rather than patients’ individual
characteristics. The degree of variability in the use of
anticoagulants that was independent of patient characteris-
tics highlights the need for greater guidance on how to most
effectively and efficiently use these medicines.
At the core of this issue is the need for more comparative
effectiveness studies, ideally with a focus on the heteroge-
neity of treatment benefit among patients, so that all
anticoagulant decisions can be evidence based and patient
tailored. If these medicines were truly interchangeable in
terms of benefits, risks, and costs, then finding such variation
in practice patterns would be inconsequential. However,
available studies suggest otherwise,6,8 and the most recent































Figure 3. Median use of each anticoagulant strategy by hospital
anticoagulant phenotype (percentages do not add up to 100% due
to variability around each median estimate). Bival indicates
bivalirudin; LMWH, low-molecular-weight heparin; UFH, unfrac-
tionated heparin.
Table 3. Association of Hospital Characteristics and Anticoagulant Use Phenotypes
OR (95% CI) (REF: Low Bival, Low LMWH)
High Bival, High LMWH High Bival, Low LMWH Low Bival, High LMWH
Rural population (vs urban) 1.1 (1.0 to 1.2) 1.1 (1.0 to 1.2) 0.7 (0.7 to 0.8)
Nonteaching status (vs teaching) 0.6 (0.5 to 0.6) 0.6 (0.6 to 0.6) 0.4 (0.4 to 0.5)
Number of beds (REF: >400)
<200 beds 1.5 (1.5 to 1.6) 1.8 (1.7 to 1.9) 1.8 (1.7 to 1.9)
200 to 400 beds 9.5 (8.3 to 11.0) 5.3 (4.7 to 6.1) 14.8 (12.9 to 16.9)
Census region (REF: West)
Midwest 1.4 (1.3 to 1.5) 0.5 (0.5 to 0.5) 3.6 (3.3 to 3.9)
Northeast 0.1 (0.1 to 0.1) 0.4 (0.4 to 0.4) 1.8 (1.6 to 2)
South 3.2 (3 to 3.4) 0.7 (0.7 to 0.8) 9.7 (8.9 to 10.5)
Adjusting for patient age group, gender, STEMI, and comorbidities. High/low users of bivalirudin and LMWH based on above/below median use in the study cohort (37.4.1% and 9.8%,
respectively). Bival indicates bivalirudin; LMWH, low-molecular-weight heparin; OR, odds ratio; STEMI, ST-elevation myocardial infarction.
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as to the optimal strategy.10,24 Our hospital-based analysis
did not find 1 particular anticoagulation phenotype that was
superior in terms of patient outcomes. Consequently, more
work is needed to define the optimal way to minimize site-
level variability and improve patient outcomes.
Potential Explanations
The discrepancy between the patient- and hospital-level
analyses could indicate that anticoagulants are not being
applied in a manner consistent with the risk profile of the
patient. For example, if a high bivalirudin-using hospital uses
bivalirudin more often in patients with low bleeding risk (a
documented risk-treatment paradox25), then bleeding could
be reduced at the patient level but the overall bleeding rate
for the hospital would be minimally affected (as the patients in
whom bivalirudin is used have an overall low risk of bleeding).
However, hospitals that use bivalirudin less often, but more
selectively in high bleeding-risk patients, may have lower
overall bleeding rates. Nevertheless, this is predicated on an
assumption that bivalirudin reduces bleeding risk in patients
with MI, an assumption that a recent trial has questioned in
patients undergoing primary PCI.10
However, the disconnect between the patient- and hospi-
tal-level outcomes analyses may also indicate that other
processes of care employed at these hospitals that may be
associated with bleeding risk (eg, access site management,
postprocedure monitoring) could account for the observed
differences in RSBRs beyond anticoagulation management.
This finding is supported by recent work in the National
Cardiovascular Data Registry, where greater than two thirds of
the variation in hospitals’ bleeding rates in the setting of an MI
were found to persist after accounting for case mix and
treatment strategies, with anticoagulant and antiplatelet
therapies explaining only 16% of variation in hospital-adjusted
bleeding rates.26
Further work is needed both to understand how to apply
these anticoagulants most effectively and efficiently and to
identify other aspects of care that contribute to bleeding in
order to improve the outcomes of invasively managed MI
patients. Preliminary work has demonstrated that simply
providing estimates of bleeding risk at the point of care
resulted in more targeted bivalirudin use in high-risk patients
and reductions in bleeding.27 However, it is unclear whether
the improvement in outcomes is mediated through the
specific anticoagulant used versus the application of ancillary
strategies such as access site management, when the
bleeding risk of the patient is known. More studies are
needed to better understand the specifics of this patient-
directed treatment strategy and whether or not it can be
applied on a larger scale.
Limitations
There are potential limitations to consider when interpreting
our study. First, while we were able to establish that there
was substantial variability in the use of different anticoagu-
lants that was based purely on local practice patterns, the
ideal pattern of use, which minimizes ischemic and bleeding
complications while also minimizing costs, is currently
unknown. In addition, we defined high and low users of
LMWH and bivalirudin based on median levels of use. While
we did perform a sensitivity analysis defining the upper
quartile of use as a high user, we were unable to determine
the appropriateness of use—either overuse or underuse—
among hospitals, and it is possible that there is an ideal
Table 4. Association of Anticoagulant Treatment Strategies
and Patient Characteristics With In-Hospital Bleeding Events
OR (95% CI)
Anticoagulants (REF: UFH only)
UFH+LMWH 0.98 (0.82 to 1.17)
LMWH only 0.84 (0.71 to 1.00)
Bivalirudin (any) 0.84 (0.76 to 0.93)
Patient factors
Age (REF ≥75 years)
18 to <55 0.45 (0.40 to 0.51)
55 to <65 0.56 (0.50 to 0.63)
65 to <75 0.78 (0.70 to 0.87)
Female 1.51 (1.39 to 1.65)
Hypertension 0.87 (0.79 to 0.95)
Congestive heart failure 3.77 (2.46 to 5.77)
Peripheral vascular disease 1.37 (1.22 to 1.55)
Diabetes with complications 1.22 (1.02 to 1.45)
Renal failure 1.64 (1.46 to 1.84)
Chronic pulmonary disease 1.53 (1.39 to 1.69)
Liver disease 1.81 (1.34 to 2.44)
Weight loss 2.48 (2.04 to 3.01)
Deficiency anemia 1.17 (1.04 to 1.30)
Chronic blood loss anemia 6.64 (5.25 to 8.40)
Coagulopathy 2.35 (2.04 to 2.71)
Fluid and electrolyte disorder 2.43 (2.22 to 2.67)
Metastatic cancer 1.81 (1.20 to 2.72)
Solid tumor without metastasis 1.88 (1.42 to 2.49)
Paralysis 1.64 (1.22 to 2.20)
ST-elevation MI 1.24 (1.14 to 1.36)
Glycoprotein IIb/IIIa inhibitor 1.60 (1.45 to 1.76)
c-index=0.76. LMWH indicates low-molecular-weight heparin; MI, myocardial infarction;
OR, odds ratio; UFH, unfractionated heparin.
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pattern of use that our approach was unable to identify. Thus,
further work is needed to determine the ideal balance of
anticoagulants in various patient populations.
Second, we did not limit or stratify our analyses based on
ST-elevation. While this certainly affects both the choice of
anticoagulant and also the risk of bleeding, we wished to
conduct a broader analysis of MI patients and thus elected to
adjust for this important factor in the multivariate models
instead of dividing the analytic population. Third, given the
complexity of the multivariate models and the need to identify
meaningful hospital phenotypes, we did not include all
possible combinations of anticoagulants and instead used 4
broad categories, as has been done previously.28 In addition,
we did not further stratify by glycoprotein IIb/IIIa use, which
was used less commonly in patients who received bivalirudin.
However, we did adjust for the use of these medications in all
of our models, in order to account for these differences
across the anticoagulants. Fourth, we were unable to
determine the access site for the coronary angiogram, which
could impact bleeding. While it is possible that physicians who
use more femoral access also use more bivalirudin to
compensate for the increased risk of bleeding, this could
not explain why the patient-level results showed benefit with
bivalirudin that was not observed in the hospital-level results.
Fifth, our patient-level results agree with those of many,6,8 but
not all,10 anticoagulant trials. Importantly, our work was
designed as an investigation of patterns of care and the
association of these patterns with outcomes rather than as a
comparative effectiveness study.
Finally, we relied on ICD-9-CM codes, not adjudication of
hospital records, both to identify MI patients and the
incidence of clinically relevant bleeding. Our rate of MI
patients not treated with an anticoagulant was 13%
compared with 6% found in the National Cardiovascular
Data Registry Acute Coronary Treatment and Intervention
Outcomes Network Registry–Get With the Guidelines.28 While
our study design of analyzing only patients who received an
anticoagulant somewhat accounts for this first point, it is
possible that some patients included in our analyses were
miscoded as having had MIs. In addition, using administrative
coding to base our categorization of MIs as non-ST-elevation
or ST-elevation likely resulted in some misclassification.
However, as this was only used for adjustment in the models
and was not a key variable in the results, we believe the
results are unlikely to have been materially affected. For the
bleeding events, while we are likely underestimating the true
rate of bleeding in this population (4% in our study versus
10% in the national registry28), it is unlikely that this
Table 5. Anticoagulant Use Phenotypes and Bleeding, Mortality, and Length of Stay
Anticoagulant Use Phenotypes
High Bival, High LMWH
(n=54)
High Bival, Low LMWH
(n=75)
Low Bival, High LMWH
(n=74)
Low Bival, Low LMWH
(n=54) P Value
Observed bleeding rate, % 3.4 (2.3 to 5.4) 3.4 (2.3 to 4.9) 4.0 (2.7 to 5.6) 4.4 (3.4 to 5.6) 0.033
RS-bleeding rate, adjusted for patient factors, % 4.1 (3.7 to 4.5) 4 (3.7 to 4.4) 4.1 (3.8 to 4.6) 4.2 (3.9 to 4.6) 0.338
RS-bleeding rate, also adjusted for anticoagulant, % 4.1 (3.7 to 4.5) 4.1 (3.8 to 4.4) 4.1 (3.8 to 4.6) 4.2 (3.8 to 4.5) 0.845
RS-mortality rate, % 2.3 (2.1 to 2.6) 2.2 (2 to 2.6) 2.3 (2 to 2.5) 2.2 (2 to 2.5) 0.377
RS-length of stay, days 3.0 (2.7 to 3.2) 2.9 (2.7 to 3.2) 3.0 (2.9 to 3.4) 3.1 (2.7 to 3.3) 0.066
All values are expressed as median (IQR). High/low users of bivalirudin and LMWH based on above/below median use in the study cohort (37.4% and 9.8%, respectively). Bival indicates
bivalirudin; IQR, interquartile range; LMWH, low-molecular-weight heparin; RS, risk standardized.
Table 6. Anticoagulant Use Phenotypes and Bleeding, Mortality, and Length of Stay, With High Use Defined as in the Top Quartile
of Utilization
Anticoagulant Use Phenotypes
High Bival, High LMWH
(n=5)
High Bival, Low LMWH
(n=60)
Low Bival, High LMWH
(n=59)
Low Bival, Low LMWH
(n=133) P Value
Observed bleeding rate, % 3.4 (1.2 to 6.8) 3.5 (2.3 to 5.0) 4.1 (3.1 to 5.6) 3.8 (2.7 to 5.4) 0.345
RS-bleeding rate, adjusted for patient factors, % 4.0 (3.9 to 4.4) 4.2 (3.8 to 4.4) 4.1 (3.8 to 4.6) 4.0 (3.8 to 4.5) 0.827
RS-bleeding rate, also adjusted for anticoagulant, % 4.1 (3.9 to 4.4) 4.2 (3.8 to 4.4) 4.1 (3.8 to 4.7) 4.0 (3.8 to 4.4) 0.464
RS-mortality rate, % 2.3 (2.3 to 2.4) 2.2 (2.0 to 2.5) 2.4 (2.1 to 2.6) 2.2 (2.0 to 2.5) 0.123
RS-length of stay, days 2.6 (2.5 to 3.1) 2.8 (2.6 to 3.1) 3.2 (2.9 to 3.5) 3.0 (2.7 to 3.2) <0.001
All values are expressed as median (IQR). High users of bivalirudin and LMWH based on the highest quartile of use in the study cohort (66.5% and 19.7%, respectively). Bival indicates
bivalirudin; IQR, interquartile range; LMWH, low-molecular-weight heparin; RS, risk standardized.
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undercoding was biased among hospitals and thus should not
have affected our observed associations between treatments
and hospital phenotypes with bleeding outcomes. Further-
more, analyses in warfarin-treated patients have shown ICD-9-
CM codes to be reasonably reliable for identifying clinically
relevant bleeding events.29
Conclusions
In a large database of US hospitals, we found substantial site-
level variability in the choice of anticoagulants for patients
with an acute MI who were invasively managed, even after
accounting for patient factors. When we phenotyped hospitals
by their pattern of anticoagulant use, no single pattern was
found to be clinically superior. While the ideal pattern of use
of anticoagulants—one that minimizes ischemic and bleeding
complications as well as costs—is not known, it is important
to understand the current patterns of use and the clinical
outcomes associated with them. The amount of variability that
we identified that was based on local practice patterns and
not patient characteristics highlights the need for more
studies to determine which patients would benefit most from
the anticoagulant choices. Such studies are needed to help
inform our guidelines and clinical practice such that these
therapies can be applied effectively and efficiently, and
individualized to patients’ needs.
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